| Literature DB >> 20646313 |
Ines C Kiphuth1, Peter D Schellinger, Martin Köhrmann, Jürgen Bardutzky, Hannes Lücking, Stephan Kloska, Stefan Schwab, Hagen B Huttner.
Abstract
INTRODUCTION: There are only limited data on the long-term outcome of patients receiving specialized neurocritical care. In this study we analyzed survival, long-term mortality and functional outcome after neurocritical care and determined predictors for good functional outcome.Entities:
Mesh:
Year: 2010 PMID: 20646313 PMCID: PMC2945110 DOI: 10.1186/cc9192
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flowchart of patient selection.
Demographic and clinical data
| All | Ischemia | ICH | SAH | Meningoencephalitis | Epilepsy | GBS/MG | Neurodeg/Encephalopathy | Neoplasm | Intoxication | Temporarily monitored | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 733 | 247 (33.7) | 210 (27.4) | 38 (5.2) | 49 (6.7) | 93 (12.7) | 25 (3.4) | 22 (3.0) | 22 (3.0) | 27 (3.7) | ||
| 67 (18 to 95) | 72 (21 to 93) | 70 (35 to 95) | 56 (19 to 84) | 63 (27 to 85) | 59 (18 to 93) | 58 (23 to 78) | 66 (23 to 90) | 65 (39 to 78) | 53 (29 to 78) | ||
| 350 (47.7) | 111 (44.9 ) | 100 (47.6) | 20 (52.6) | 26 (53.1) | 48 (51.6) | 14 (56) | 14 (63.6) | 8 (36.4) | 9 (33.3) | ||
| 635 (86.6) | 227 (91.9) | 198 (94.3) | 37 (97.4) | 43 (87.8) | 71 (76.3) | 24 (96.0) | 8 (36.4) | 4 (18.2) | 23 (85.2) | ||
| 4 (0 to 87) | 4 (0 to 57) | 5 (0 to 53) | 4 (0 to 63) | 4 (0 to 84) | 1 (0 to 87) | 6 (0 to 57) | 3 (1 to 50) | 3 (0 to 17) | 3 (0 to 19) | ||
| 450 (61.4) | 148 (59.9) | 140 (66.7) | 20 (52.6) | 42 (85.7) | 48 (51.6) | 16 (64.0) | 18 (81.8) | 8 (36.4) | 20 (74.1) | ||
| 3 (0 to 83) | 4 (0 to 43) | 5 (0 to 53) | 1(0 to 60) | 4 (0 to 83) | 0 (0 to 63) | 6 (0 to 49) | 3 (0 to 50) | 0 (0 to 13) | 3 (0 to 14) | ||
| 165 (22.5) | 53 (21.5) | 75 (35.7) | 12 (31.6) | 3 (6.1) | 5 (5.4) | 1 (4.0) | 4 (18.2) | 7 (31.8) | 5 (18.5) | ||
| 292 (39.8) | 100 (41.5) | 121 (59.0) | 18 (48.6) | 6 (12.8) | 14 (16.3) | 1 (4.2) | 11 (55.0) | 15 (78.9) | 6 (24.6) | ||
| 208 (28.4) | 33 (13.7) | 40 (19.5) | 11 (29.7) | 28 (59.6) | 57 (66.3) | 16 (66.7) | 5 (25.0) | 1 (5.3) | 17 (68.0) |
Demographic and clinical characteristics of all patients (n = 796) including a separate analysis for admission diagnosis (intention-to-treat cohort).
Patients who were excluded for the per protocol-analysis are highlighted in bold. (PS: All patients monitored only temporarily (right column) are not included in the overall numbers (left column). Patients lost to follow up are not included in mortality and functional outcome after one year.)
Abbreviations: ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; Neurodeg, neurodegenerative disease; n, number; d, days.
Figure 2Functional status after one year, in-hospital mortality and mortality after one year for all patients treated per protocol (.
Predictors for functional outcome
| Good outcome (mRS ≤ 2) | |||
|---|---|---|---|
| Exp(Coef) | 95% CI | ||
| Age | 0.834 | 0.794 to 0.872 | < 0.0001 |
| SEX (female) | 1.265 | 0.554 to 1.864 | 0.57645 |
| TISS-28 on Day 1 | |||
| | |||
| | |||
| | |||
| TISS-28 at discharge | |||
| | |||
| | |||
| | |||
| SAH | 0.636 | 0.273 to 1.198 | 0.63532 |
| Meningoencephalitis | 1.412 | 0.996 to 3.238 | 0.12432 |
| Epilepsy | 1.433 | 0.233 to 2.346 | 0.73255 |
| 0.786 | 0.435 to 0.823 | 0.00245 | |
| Hospital LOS | 0.509 | 0.272 to 1.279 | 0.17647 |
| Ischemia | 0.345 | 0.245 to 1.101 | 0.11458 |
| Neurodeg./Encephalopathy | 0.705 | 0.297 to 1.354 | 0.15478 |
| Intoxication | 1.399 | 0.964 to 2.648 | 0.27261 |
Univariate and multivariate regression analysis for parameters predicting a good functional outcome (mRS 0 to 2) one year after neurocritical care. Analysis of all patients receiving specialized neurocritical care (n = 666). Parameters that reached significance (P < 0.05) are expressed in bold. Parameters that showed a statistical trend (P < 0.1) in the univariate analysis are expressed in italics.
Abbreviations: CI, confidence interval; LOS, length of stay; ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; Neurodeg, neurodegenerative disease